Combination of | |
---|---|
Neostigmine | Cholinesterase inhibitor |
Glycopyrronium bromide | Antimuscarinic agent |
Clinical data | |
Trade names | Prevduo |
Other names | Neostigmine methylsulfate/glycopyrrolate, glycopyrronium bromide/neostigmine metilsulfate |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
Neostigmine/glycopyrronium bromide, sold under the brand name Prevduo , is a fixed-dose combination medication used for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.[2] It contains neostigmine as the methylsulfate, a cholinesterase inhibitor, and glycopyrronium bromide, an antimuscarinic agent.[2]
Neostigmine/glycopyrronium bromide was approved for medical use in the United Kingdom in 2007,[1] and in the United States in February 2023.[3]
Neostigmine/glycopyrronium bromide is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following non-depolarizing neuromuscular blocking agent reversal administration.[3]
((cite web))
: CS1 maint: archived copy as title (link)
mAChRsTooltip Muscarinic acetylcholine receptors |
| ||||
---|---|---|---|---|---|
Precursors (and prodrugs) | |||||